JP2012524103A5 - - Google Patents

Download PDF

Info

Publication number
JP2012524103A5
JP2012524103A5 JP2012506209A JP2012506209A JP2012524103A5 JP 2012524103 A5 JP2012524103 A5 JP 2012524103A5 JP 2012506209 A JP2012506209 A JP 2012506209A JP 2012506209 A JP2012506209 A JP 2012506209A JP 2012524103 A5 JP2012524103 A5 JP 2012524103A5
Authority
JP
Japan
Prior art keywords
phenyl
azabicyclo
oxa
alkyl
oct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012506209A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012524103A (ja
JP5649643B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/031191 external-priority patent/WO2010120998A1/en
Publication of JP2012524103A publication Critical patent/JP2012524103A/ja
Publication of JP2012524103A5 publication Critical patent/JP2012524103A5/ja
Application granted granted Critical
Publication of JP5649643B2 publication Critical patent/JP5649643B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012506209A 2009-04-17 2010-04-15 ピリミジン化合物、ｍＴＯＲキナーゼおよびＰＩ３キナーゼ阻害剤としてのそれらの使用、ならびにそれらの合成 Expired - Fee Related JP5649643B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17013809P 2009-04-17 2009-04-17
US61/170,138 2009-04-17
PCT/US2010/031191 WO2010120998A1 (en) 2009-04-17 2010-04-15 Pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses

Publications (3)

Publication Number Publication Date
JP2012524103A JP2012524103A (ja) 2012-10-11
JP2012524103A5 true JP2012524103A5 (enExample) 2013-04-04
JP5649643B2 JP5649643B2 (ja) 2015-01-07

Family

ID=42269326

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012506209A Expired - Fee Related JP5649643B2 (ja) 2009-04-17 2010-04-15 ピリミジン化合物、ｍＴＯＲキナーゼおよびＰＩ３キナーゼ阻害剤としてのそれらの使用、ならびにそれらの合成

Country Status (6)

Country Link
US (1) US8835429B2 (enExample)
EP (1) EP2419432B9 (enExample)
JP (1) JP5649643B2 (enExample)
CA (1) CA2755554C (enExample)
ES (1) ES2439793T3 (enExample)
WO (1) WO2010120998A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2542536B1 (en) 2010-03-04 2015-01-21 Cellzome Limited Morpholino substituted urea derivatives as mtor inhibitors
WO2012122383A2 (en) * 2011-03-09 2012-09-13 Avila Therapeutics, Inc. Pi3 kinase inhibitors and uses thereof
WO2012136622A1 (en) 2011-04-04 2012-10-11 Cellzome Limited Dihydropyrrolo pyrimidine derivatives as mtor inhibitors
CA2849189A1 (en) 2011-09-21 2013-03-28 Cellzome Limited Morpholino substituted urea or carbamate derivatives as mtor inhibitors
JP5995977B2 (ja) 2011-10-07 2016-09-21 セルゾーム リミテッド Ｍｔｏｒ阻害剤としてのモルホリノ置換二環式ピリミジン尿素またはカルバメート誘導体
PH12014500973A1 (en) * 2011-11-01 2014-06-16 Exelixis Inc Phosphatidylinositol 3-kinase inhibitors for the treatment of lymphoproliferative malignancies
CN104230952B (zh) * 2014-08-16 2017-02-01 沈阳药科大学 含有嘧啶骨架的化合物及其制备方法和用途
AU2015366357B2 (en) 2014-12-17 2018-07-19 Shanghai Haiyan Pharmaceutical Technology Co. Ltd. 2-morpholin-4,6-disubstituted pyrimidine derivative, and preparation method and pharmaceutical use thereof
GB202415232D0 (en) 2024-10-16 2024-11-27 Nacamed As Composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9009A (en) * 1852-06-08 Bat-trap
US20060240014A1 (en) * 2003-06-03 2006-10-26 Beth Israel Deaconess Medical Center Methods and compounds for the treatment of vascular stenosis
GB0520657D0 (en) * 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
GB0525083D0 (en) * 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
JP5534811B2 (ja) * 2006-08-24 2014-07-02 アストラゼネカ アクチボラグ 増殖性疾患の治療に有用なモルホリノピリミジン誘導体
JP2010527924A (ja) * 2007-05-18 2010-08-19 メルク・シャープ・エンド・ドーム・コーポレイション オキソ架橋ジアゼパンオレキシン受容体アンタゴニスト
CA2702838A1 (en) * 2007-10-16 2009-04-23 Wyeth Llc Thienopyrimidine and pyrazolopyrimidine compounds and their use as mtor kinase and pi3 kinase inhibitors

Similar Documents

Publication Publication Date Title
ES2728163T3 (es) Compuestos de triazina como inhibidores de PI3 cinasa y mTOR
JP2011500702A5 (enExample)
RS62289B1 (sr) Difluorometil-aminopiridini i difluorometil-aminopirimidini
JP5649643B2 (ja) ピリミジン化合物、ｍＴＯＲキナーゼおよびＰＩ３キナーゼ阻害剤としてのそれらの使用、ならびにそれらの合成
US10022381B2 (en) Triazine compounds as PI3 kinase and mTOR inhibitors
PE20061067A1 (es) Derivados de pirimidina
TH180843A (th) อนุพันธ์อะมิโน ไพริมิดีนชนิดใหม่
HK1203199B (en) Triazine compounds as pi3 kinase and mtor inhibitors
HK1157328B (en) Triazine compounds as pi3 kinase and mtor inhibitors
TH104496B (th) สารยับยั้ง pde10 ประเภทไพริมิดีน
TH147865A (th) สารยับยั้ง pde10 ประเภทไพริมิดีน